A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma (NCT05625399)
A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination Versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants With Previously Untreated Metastatic or Unresectable Melanoma
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma.
Who can join: Review the eligibility criteria below.
Location: Local Institution - 0125 — Phoenix, Arizona
Age range: 12 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (149 Sites)
Showing the first 25 of 149 sites.
- Local Institution - 0125 — Phoenix, Arizona
- Local Institution - 0189 — Springdale, Arkansas
- Local Institution - 0098 — Los Angeles, California
- Local Institution - 0093 — Orange, California
- Local Institution - 0123 — Stanford, California
- Local Institution - 0113 — Englewood, Colorado
- Local Institution - 0114 — Jacksonville, Florida
- Local Institution - 0146 — Baltimore, Maryland
- Local Institution - 0071 — Rochester, Minnesota
- Local Institution - 0013 — Omaha, Nebraska
- Local Institution - 0169 — Cleveland, Ohio
- Local Institution - 0139 — Easton, Pennsylvania
- Local Institution - 0124 — Philadelphia, Pennsylvania
- Local Institution - 0122 — Murray, Utah
- Local Institution - 0115 — Fairfax, Virginia
- Local Institution - 0050 — Coffs Harbour, New South Wales
- Local Institution - 0175 — Orange, New South Wales
- Local Institution - 0172 — Port Macquarie, New South Wales
- Local Institution - 0118 — Wagga Wagga, New South Wales
- Local Institution - 0184 — Waratah, New South Wales
- Local Institution - 0033 — Westmead, New South Wales
- Local Institution - 0055 — Wollstonecraft, New South Wales
- Local Institution - 0090 — Birtinya, Queensland
- Local Institution - 0008 — Bendigo, Victoria
- Local Institution - 0059 — Box Hill, Victoria
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Melanoma
- Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy — San Francisco, California
- An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) — Tucson, Arizona
- Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. — CABA, Buenos Aires
- Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients — Santa Monica, California
- NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma — Boston, Massachusetts
- A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma — Orlando, Florida
Explore by condition: All Melanoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.